Announced Thu, 16 Oct · 17:27 IST

Appointment of Mr. Rishi Upadhaya as Company Secretary and compliance Officer of the Company

Management Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The board of Asston Pharmaceuticals, at its meeting on 16 October 2025, approved the appointment of Mr. Rishi Upadhaya as Company Secretary and Compliance Officer. It also appointed a new internal auditor (M/s Yash A. Jain & Associates) and Mr. Yogesh Supekar as an Additional Non-Executive Non-Independent Director. Additionally, the board cleared two borrowing decisions: an unsecured, interest-free loan of up to Rs. 3 crore from existing directors, and a secured loan of up to Rs. 2.70 crore from HDFC Bank to fund the purchase of a commercial space.

Likely market impact

These are routine governance and financing actions. The interest-free director loan of Rs. 3 crore is a related-party transaction that signals promoter financial support, while the HDFC loan will increase debt on the books but is backed by a tangible commercial asset. No material governance red flags or leadership exits are evident from this filing.